> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approval Reciprocity Bill Reintroduced
- URL: https://www.fdaweb.com/fda-approval-reciprocity-bill-reintroduced/
- Published: 2023-05-23T12:00:00.000Z
- Updated: 2026-09-14T18:33:40.000Z
- Author: David McFarland
- Tags: Drugs, Devices, #legacy-id-D5154519

Rep. **Chip Roy** (R-TX) has reintroduced the [Reciprocity Ensures Streamlined Use of Lifesaving Treatments](http://roy.house.gov/sites/evo-subsites/roy.house.gov/files/evo-media-document/result-act-2023.pdf?ref=fdaweb.com)" (RESULT) Act that would expedite FDA’s approval process for potentially lifesaving medicines by allowing “reciprocal approval” of drugs approved in other trusted nations. “The American people should not have to wait years and years for bureaucrats at the FDA to sign off on medicines that are already approved in other trusted countries,” Roy said in a [release](https://roy.house.gov/media/press-releases/rep-chip-roy-pushes-improve-americans-access-lifesaving-medicine?ref=fdaweb.com). Read the full legislation [here](http://roy.house.gov/sites/evo-subsites/roy.house.gov/files/evo-media-document/result-act-2023.pdf?ref=fdaweb.com).

Roy first introduced the RESULT Act in [3/2020](http://roy.house.gov/media/press-releases/rep-roy-introduces-result-acts-amid-coronavirus-pandemic?ref=fdaweb.com). The bill would require FDA to quickly review drug, device, and biologic applications from companies that have products approved and sold in developed and reliable countries. Senators **Ted Cruz** (R-TX) and **Mike Lee** (R-UT) have also introduced companion legislation in the Senate.

Under the mesasure, the Food, Drug and Cosmetic Act would be amended to allow for reciprocal approval of drugs, devices and biologics from foreign sponsors in certain trusted, developed countries including the EU member countries, United Kingdom, Israel, Australia, Canada and Japan. It would provide the agency with a 30-day window to approve or deny a sponsor's application for reciprocity, and it grants Congress the authority to disapprove a denied application and override an FDA decision with a majority vote via a joint resolution.